Prevalence, Associated Factors, and Outcomes of Clostridioides difficile Infection Across Gastrointestinal Cancer Subtypes: A US Nationwide Analysis
This nationwide US analysis of over 3.5 million gastrointestinal cancer hospitalizations reveals that Clostridioides difficile infection affects approximately 1.4% of cases, is most prevalent in anal cancer and strongly associated with inflammatory bowel disease, and significantly increases risks of mortality, organ failure, and healthcare costs.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the complex ecosystem of the human body, the gut is home to trillions of bacteria that help digest food and protect against invaders. Usually, these microbes exist in a delicate balance. However, when a person takes antibiotics to fight an infection, or when their immune system is weakened by illness, this balance can shatter. A specific bacterium called Clostridioides difficile, often shortened to C. diff, can then take over. This germ produces powerful toxins that cause severe diarrhea and inflammation of the colon. While anyone can get this infection, it is particularly dangerous for people already fighting serious diseases, as their bodies are less able to fight back. For patients with cancers of the digestive system, the risk is heightened by frequent hospital stays, surgeries, and the heavy use of medications that can disrupt the gut's natural defenses.
A team of researchers at the University of Kansas Medical Center set out to understand just how often this infection strikes people hospitalized with gastrointestinal cancers, and what happens to them when it does. They looked at a massive collection of hospital records from across the United States, covering six years from 2018 to 2023. This database included information on more than 3.5 million hospital stays involving adults with active cancers of the esophagus, stomach, intestines, liver, pancreas, and other digestive organs. By sorting through these records, the scientists could see who developed the infection, what factors made them more likely to get it, and how the infection changed their time in the hospital.
The study found that C. difficile infection occurred in about 1.37 percent of these hospital stays, which translates to roughly one in every 73 patients with digestive tract cancer. While the infection was present in all types of digestive cancers, it was most common in patients with anal cancer, where it appeared in about 2.3 percent of cases. The researchers also noticed a positive trend over time: the rate of infection dropped from 1.63 percent in 2018 to 1.22 percent in 2023. This decline likely reflects broader improvements in how hospitals prevent infections and manage the use of antibiotics.
When the scientists dug deeper to find out who was most at risk, they identified several clear patterns. The strongest link was found in patients who also had inflammatory bowel disease, a chronic condition that causes swelling and damage in the digestive tract. These patients were more than twice as likely to develop the infection compared to those without the condition. Other significant risk factors included chronic kidney disease, a history of organ transplantation, and HIV/AIDS. The researchers also found that older age, being female, and having an unplanned or emergency hospital admission increased the odds of infection. Surprisingly, patients with obesity were less likely to get the infection, though the authors noted this might be due to how medical records are filled out rather than a true protective effect.
The impact of the infection on a patient's health was severe. Patients who developed C. difficile were significantly more likely to die during their hospital stay compared to those who did not. They were also much more likely to require intensive medical support, such as being placed on a breathing machine, receiving drugs to keep their blood pressure up, or needing dialysis to support their kidneys. The infection also took a heavy toll on the healthcare system. Patients with the infection stayed in the hospital about 65 percent longer than those without it, and the cost of their care was roughly 40 percent higher.
The effects were not the same for every type of cancer. While the infection consistently led to longer hospital stays across all the different cancer types studied, its link to death and severe organ failure varied. For example, the infection was strongly tied to higher death rates specifically in patients with stomach cancer, but the connection was less clear for other types. In patients with anal cancer, the infection was not only the most common but also showed the strongest independent link to the disease itself, suggesting that the unique treatments for this cancer, such as combined chemotherapy and radiation, might create a perfect environment for the infection to thrive.
This large-scale analysis provides a clear picture of the burden C. difficile places on patients with digestive cancers. It confirms that while the infection is becoming slightly less common, it remains a serious complication that increases the risk of death, the need for life-support measures, and the length of hospitalization. The findings highlight that patients with inflammatory bowel disease, kidney problems, or a history of organ transplants need extra vigilance. By understanding who is most vulnerable and how the infection changes outcomes, doctors can focus their prevention efforts more effectively, ensuring that patients fighting cancer do not have to face this additional, life-threatening hurdle.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.